focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCPT.L Regulatory News (CPT)

  • There is currently no data for CPT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

4 Feb 2016 16:00

RNS Number : 1415O
Frontier Resources International
04 February 2016
 

For immediate release

 

4 February 2016

 

Frontier Resources International Plc

("Frontier" or the "Company")

Corporate update

 

Proposed funding

The Board of Frontier (AIM Ticker: FRI) announces that the Company is at an advanced stage of preparations on a proposed issue of new ordinary shares with existing and new investors at an issue price of 0.03p per new ordinary share (the "Subscription Price") to raise approximately £1.4 million before expenses (the "Proposed Subscription"). As previously announced, the Company has an urgent need to arrange additional funding for its immediate working capital requirements over and above the potential commitments in respect of its oil exploration projects.

 

The proceeds of the Proposed Subscription, should it proceed, would be used to provide working capital for the Company and to support the investment in new projects. The Board does not currently intend to provide any further capital to the Company's existing oil exploration projects, the future of which the Board would consider following completion of the Proposed Subscription.

 

The Board is acutely aware of the impact of dilution of the Proposed Subscription on existing shareholders but believes that the costs and requirements of an open offer or rights issue are such that it will not be practicable or cost effective to implement and could not be achieved in the timeframe required. In order to reduce the impact of dilution and provide existing shareholders with some ability to participate, should they so choose, on similar terms to the Proposed Subscription, the Board intends that, subject to certain regulatory considerations relating to marketing securities in certain jurisdictions, to issue new warrants to existing shareholders on a pro rata basis of one warrant for every one ordinary share held in the Company exercisable at the Subscription Price. Further terms of the warrants will be set out in the announcement of the Proposed Subscription should it proceed.

 

Oman update and AIM status

As announced on 16 December 2015, Frontier's request to extend the initial term of the Group's 100%-owned Block 38 located in the Rub Al Khali Basin in the southwest of the Sultanate of Oman ("Block 38 EPSA") for 24 months (until 25 November 2017) was granted, subject to Frontier providing a bank guarantee for the amount required to conduct the amended work programme, which it must do by no later than 4 February 2016 ("Funding Deadline").

 

While the potential farm-out process in respect of Block 38 EPSA has been ongoing for some time, and the Company retained the services of a Dallas-based adviser to assist and provide general transaction advice on this process, the Board has been unable to secure any farm-out partner on credible terms. Furthermore, there has been no investor support for an equity issue to provide further funding for the Company's interest in Block 38 EPSA.

 

Accordingly, the Company has been unable to raise sufficient funding and/or provide a bank guarantee for Block 38 EPSA before the Funding Deadline. The Company is seeking clarification from the relevant Oman authorities as to whether any extension of the Funding Deadline can be granted or whether the Block 38 EPSA will terminate.

 

Should the Block 38 EPSA terminate, then in accordance with AIM Rule 15, the effect would be that the Company will cease to own, control or conduct all, or substantially all, of its existing trading business, activities or assets and would therefore become an AIM Rule 15 cash shell, pursuant to which it must make an acquisition or acquisitions (or become an investing company pursuant to AIM Rule 8) which constitutes a reverse takeover under AIM Rule 14 within six months, failing which the Exchange will suspend trading in the Company's shares pursuant to AIM Rule 40.

 

Board

To support a new strategic direction for the Company, should the Proposed Subscription proceed, the Board also intends to appoint Adam Reynolds to the Board as Chairman of the Company. Mr Reynolds has a track record of implementing change strategies for companies and the Board believe that his appointment will enable the Company to develop in a new strategic direction to re-build shareholder value.

 

Mr Reynolds is currently a director of several AIM-traded companies: He is a non-executive director of EKF Diagnostics Holdings plc (a point-of-care, central laboratory, and molecular diagnostics company), Premaitha Health Plc (a company involved in the development of prenatal screening devices) and Optibiotix Health Plc (a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes). Mr Reynolds is also non-executive Chairman of New World Oil & Gas Plc and a non-executive director of Orogen Gold Plc. He is Chairman of Autoclenz Group Limited and Reyco Limited. Further information on Mr Reynolds as required by the AIM Rules will be set out in a further announcement prior to his formal appointment.

 

A further announcement will be made in due course.

 

Enquiries:

 

Frontier Resources International Plc

Neil Herbert, Chairman

 

Tel: +44 (0) 020 3475 8108

 

Beaumont Cornish (Nomad)

Michael Cornish

Roland Cornish

Emily Staples

 

Tel: +44 (0)20 7628 3396

 

Beaufort Securities Limited (Broker)

John Belliss

 

 

Tel: +44 (0)20 7382 8300

A copy of this announcement is available from the Company's website www.friplc.com

 

 

APPENDIX I

 

The following information is disclosed pursuant to paragraph (g) of Schedule Two of the AIM Rules for Companies:

 

As at the date of this announcement, Adam Reynolds does not hold any Ordinary Shares.

 

Adam Reynolds, aged 53, has held the following directorships and / or partnerships in the past 5 years:

 

Current:

Past:

Ocutec Eyecare Limited

Bcomp 415 Limited

Premaitha Health plc

Biolustre UK Ltd

Optibiotix Health plc

Wallgate Group plc

Autoclenz Group Limited

Wilton International Marketing Limited

Hubco Investments plc

Alan Bailey (Studios) Limited

Reyco Limited

Hansard Corporate Limited

Medavinci Gold Limited

Chalton Consulting Limited

Emotion Fitness Limited

React Group plc

Orogen Gold plc

Hub Capital Partners Limited

Boldwood Limited

Velvet Consultancy Ltd

EKF Diagnostics Holdings plc

Porta Communications Plc

Autoclenz Holdings Limited

Diablo Consulting Limited

New world Oil & Gas Limited

Bcomp 429 Limited

RNR Holdings Limited

Venn Life Sciences Holdings plc

Bcomp 416 Limited

Autoclenz Group Limited

 

Wallgate Group plc

Mr Reynolds was appointed as a director of Wallgate Group plc on 3 July 2008 and resigned on 28 November 2008. Wallgate Group plc was put into administration on 12 December 2008 and became subject to creditors' voluntary liquidation on 15 December 2009. The liquidator's statement of receipts of payments to 25 February 2011 showed a creditor shortfall of £419,782.12. Wallgate Group plc was subsequently dissolved on 1 June 2011.

 

Greenhills plc

Mr Reynolds was appointed as a director of Greenhills plc on 22 December 1994. He resigned on 24 January 1996. Greenhills plc was put into receivership on 8 August 1996, and an order to wind the company up was made on 19 February 1997. The receiver's abstract of receipts and payments to 6 July 1998 showed a creditor shortfall of £216,877.32. Greenhills plc was subsequently dissolved on 2 January 2001.

 

Wilton International Marketing Limited

Mr Reynolds was appointed as a director of Wilton International Marketing Limited on 10 June 2005. Wilton International Marketing Limited was put into voluntary liquidation on 14 October 2013 and was subsequently dissolved on 1 August 2014 with no shortfall to creditors.

 

There is no further information to be disclosed in relation to Mr Reynolds pursuant to paragraph (g) of Schedule Two of the AIM Rules for Companies.

 

ENDS

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFEEFTISIIR
Date   Source Headline
27th Sep 20187:00 amRNSInterim Results
21st Sep 20189:47 amRNSHolding(s) in Company
28th Aug 20187:00 amRNSHolding(s) in Company
13th Aug 201812:55 pmRNSHolding(s) in Company
13th Aug 20187:00 amRNSHolding(s) in Company
9th Aug 201812:15 pmRNSHolding(s) in Company
2nd Aug 20187:00 amRNSOversubscribed placing raises £2,000,000
17th Jul 20187:00 amRNSBoard Changes
14th Jun 201810:22 amRNSResult of AGM
22nd May 20185:13 pmRNSNotice of AGM
1st May 20187:00 amRNSFinal Results
26th Apr 201810:00 amRNSLogistics deal with major Chinese player SinoPharm
9th Apr 20188:25 amRNSConcepta manufacturing site achieves certification
29th Mar 20187:00 amRNSConcepta pre-launch myLotus in the UK
8th Mar 20187:00 amRNSmyLotus obtains approval to commence trial in UK
20th Feb 20187:00 amRNSLaunch of myLotus app in China
16th Feb 20187:00 amRNSTwo Senior Appointments and Grant of Options
15th Feb 20187:00 amRNSConcepta signs marketing contract in China
2nd Feb 20184:17 pmRNSHolding(s) in Company
29th Jan 20187:00 amRNSResults of Chinese hospital evaluations of myLotus
2nd Jan 201812:52 pmRNSChange of Broker
22nd Dec 201711:30 amRNSTrading update
14th Dec 20177:00 amRNSAssembly held in Shanghai to showcase myLotus
30th Nov 20173:05 pmRNSDirector/PDMR Shareholding
29th Nov 20179:02 amRNSHolding(s) in Company
13th Nov 20177:02 amRNSAppointment of Joint Corporate Broker
13th Nov 20177:01 amRNSOversubscribed equity fundraising of £2,000,000
13th Nov 20177:00 amRNSSales Order
6th Nov 201712:53 pmRNSTrading and Order Update
16th Oct 20177:00 amRNSmyLotus Fertility Product - China Update
19th Sep 20177:00 amRNSInterim Results
23rd Aug 201712:00 pmRNSCorporate Update
26th Jun 20177:00 amRNSDirector Shareholding
14th Jun 201712:00 pmRNSResult of AGM
13th Jun 20177:00 amRNSFirst Sales Order China and Trading Update
24th May 20174:58 pmRNSNotice of AGM
10th May 20177:00 amRNSFirst distributor agreement in China
26th Apr 20177:00 amRNSFinal Results
29th Mar 201710:00 amRNSUK Investor Show 2017
28th Mar 20177:00 amRNSDirectorate Changes
14th Feb 20171:45 pmRNSChange of Registered Office
7th Feb 20177:00 amRNSConcepta signs agreement with Selective Antibodies
9th Jan 20177:00 amRNSConcepta achieves ISO13485 accreditation
8th Dec 20167:00 amRNSAppointment China Country Manager
8th Nov 20167:09 amRNSNew manufacturing facility in Doncaster
10th Oct 20163:53 pmRNSIssue of Equity
26th Sep 20167:00 amRNSChinese Manufacturing Agreement Signed
21st Sep 20167:00 amRNSNew Laboratory Opening
18th Aug 20167:00 amRNSInterim Results
27th Jul 20164:11 pmRNSTR-1: Notification of major interest in shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.